Tumour-suppressive microRNA-224 inhibits cancer cell migration and invasion via targeting oncogenic TPD52 in prostate cancer.
Our recent study of the microRNA expression signature of prostate cancer (PCa) revealed that microRNA-224 (miR-224) is significantly downregulated in PCa tissues. Here, we found that restoration of miR-224 significantly inhibits PCa cell migration and invasion. Additionally, we found that oncogenic TPD52 is a direct target of miR-224 regulation. Silencing of the TPD52 gene significantly inhibits cancer cell migration and invasion. Moreover, TPD52 expression is upregulated in cancer tissues and negatively correlates with miR-224 expression. We conclude that loss of tumour-suppressive miR-224 enhances cancer cell migration and invasion in PCa through direct regulation of oncogenic TPD52.
Department of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan; Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.
Yusuke
Y
Goto
Department of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan; Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.
Rika
R
Nishikawa
Department of Urology, Teikyo University Chiba Medical Centre, Chiba, Japan.
Satoko
S
Kojima
Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Takeshi
T
Chiyomaru
Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Hideki
H
Enokida
Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Satoru
S
Inoguchi
Department of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan.
Takashi
T
Kinoshita
Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.
Miki
M
Fuse
Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.
Shinichi
S
Sakamoto
Department of Urology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Masayuki
M
Nakagawa
Department of Urology, Teikyo University Chiba Medical Centre, Chiba, Japan.
Yukio
Y
Naya
Department of Urology, Chiba University Graduate School of Medicine, Chiba, Japan.
Tomohiko
T
Ichikawa
Department of Functional Genomics, Chiba University Graduate School of Medicine, Chiba, Japan. Electronic address: naoseki@faculty.chiba-u.jp.
Naohiko
N
Seki
D000368:Aged; D000369:Aged, 80 and over; D015153:Blotting, Western; D002460:Cell Line; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics*; D049109:Cell Proliferation; D015972:Gene Expression Regulation, Neoplastic; D016147:Genes, Tumor Suppressor; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009363:Neoplasm Proteins / Q000235:genetics* / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D034622:RNA Interference; D020133:Reverse Transcriptase Polymerase Chain Reaction
C546140:MIRN224 microRNA, human; D035683:MicroRNAs; D009363:Neoplasm Proteins; C114751:TPD52 protein, human
Prostate cancer; TPD52; Tumour suppressor; miR-224; microRNA